International journal of environmental research and public health · 2025
Influence of CYP2C8 Polymorphism on the Exposure to Chloroquine in Patients with Malaria by Plasmodium vivax-A Preliminary Study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Pereira de Sena Luann Wendel, Fuzii Hellen Thais, Villanova Fabiola Elizabeth, Nunes Cardoso Mello Amanda Gabryelle, de Sena Maria Pantoja Moreira, Dias Ferreira Michelle Valéria, Fernandes Vieira José Luiz
Аннотация
AIM: To assess the impact of the CYP2C82 polymorphism on chloroquine and desethylchloroquine concentrations in patients with malaria caused by P. vivax.
METHODS: A prospective study was conducted on patients with malaria in an endemic area of the Amazon basin. Liquid chromatography was employed to measure the levels of chloroquine and desethylchloroquine, while molecular methods estimated the frequency of the CYP2C82 variant.
RESULTS: This study revealed that plasma levels of chloroquine were higher in patients with the CYP2C82 polymorphism compared to those without this variant. The difference in plasma levels ranged from 5% to 26.5%. Conversely, patients with the CYP2C82 polymorphism exhibited lower levels of desethylchloroquine.
CONCLUSION: The findings of this study confirm the impairment of chloroquine metabolism by the CYP2C82 variant. However, it is noteworthy that in the dose regimen used for malaria treatment, these changes did not lead to toxic concentrations of the drug.
METHODS: A prospective study was conducted on patients with malaria in an endemic area of the Amazon basin. Liquid chromatography was employed to measure the levels of chloroquine and desethylchloroquine, while molecular methods estimated the frequency of the CYP2C82 variant.
RESULTS: This study revealed that plasma levels of chloroquine were higher in patients with the CYP2C82 polymorphism compared to those without this variant. The difference in plasma levels ranged from 5% to 26.5%. Conversely, patients with the CYP2C82 polymorphism exhibited lower levels of desethylchloroquine.
CONCLUSION: The findings of this study confirm the impairment of chloroquine metabolism by the CYP2C82 variant. However, it is noteworthy that in the dose regimen used for malaria treatment, these changes did not lead to toxic concentrations of the drug.